Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Anna Pokorska
Observed names:
Anna Pokorska-Bocci,
Anna Pokorska-bocci,
Pokorska, Anna
Institution:
Debiopharm (Switzerland)
Observed institutions:
Université Paris-Sud,
Centre National de la Recherche Scientifique,
MRC Laboratory of Molecular Biology,
Universidade de Franca,
Debiopharm (Switzerland),
PHG Foundation
show all 6
ORCID:
0009-0004-6356-875X
Observed ORCID:
0009-0004-6356-875X
OpenAlex ID:
A5074319821
’Personalized Medicine’: What’S in a Name?
2014
·
Anna Pokorska-Bocci
, Alison Stewart
, et al.
·
Personalized Medicine
·
127
A Phase I, Open-Label, Multicenter, Dose-escalation Study of the Oral Selective FGFR Inhibitor Debio 1347 in Patients with Advanced Solid Tumors Harboring FGFR Gene Alterations
2019
·
Martin H. Voss
, Cinta Hierro
, et al.
·
Clinical Cancer Research
·
120
FGFR2 Extracellular Domain In-Frame Deletions Are Therapeutically Targetable Genomic Alterations That Function as Oncogenic Drivers in Cholangiocarcinoma
2021
·
James M. Cleary
, Srivatsan Raghavan
, et al.
·
Cancer Discovery
·
96
First-in-Human Safety, Imaging, and Dosimetry of a Carbonic Anhydrase IX–Targeting Peptide, [68Ga]Ga-DPI-4452, in Patients with Clear Cell Renal Cell Carcinoma
2024
·
Michael S. Hofman
, Ben Tran
, et al.
·
Journal of Nuclear Medicine
·
89
PDF
The analysis of the transcriptional activator PrnA reveals a tripartite nuclear localisation sequence
2000
·
Anna Pokorska
, Christine Drevet
, et al.
·
Journal of Molecular Biology
·
41
Final results from the phase I study expansion cohort of the selective FGFR inhibitor Debio 1,347 in patients with solid tumors harboring an FGFR gene fusion.
2020
·
James M. Cleary
, Gopa Iyer
, et al.
·
Journal of Clinical Oncology
·
33
Sequence, exon–intron organization, transcription and mutational analysis of prnA, the gene encoding the transcriptional activator of the prn gene cluster in Aspergillus nidulans
1998
·
Béatrice Cazelle
, Anna Pokorska
, et al.
·
Molecular Microbiology
·
32
PDF
Synaptic activity induces signalling to CREB without increasing global levels of cAMP in hippocampal neurons
2003
·
Anna Pokorska
, Peter Vanhoutte
, et al.
·
Journal of Neurochemistry
·
28
FUZE clinical trial: a phase 2 study of Debio 1347 in FGFR fusion-positive advanced solid tumors irrespectively of tumor histology.
2019
·
David Michael Hyman
, Lipika Goyal
, et al.
·
Journal of Clinical Oncology
·
26
AB065. P-36. Debio 1347 in patients with cholangiocarcinoma harboring an FGFR gene alteration: preliminary results
2019
·
Matthew C. H. Ng
, Lipika Goyal
, et al.
·
HepatoBiliary Surgery and Nutrition
·
19
Evaluating Debio 1347 in Patients with FGFR Fusion-Positive Advanced Solid Tumors from the FUZE Multicenter, Open-Label, Phase II Basket Trial
2024
·
Petros Grivas
, Elena Garralda
, et al.
·
Clinical Cancer Research
·
15
PDF
Personalised medicine in the UK: challenges of implementation and impact on healthcare system
2014
·
Anna Pokorska-Bocci
, Mark Kroese
, et al.
·
Genome Medicine
·
14
PDF
Safety and efficacy of the selective FGFR inhibitor debio 1347 in phase I study patients with FGFR genomically activated advanced biliary tract cancer (BTC).
2018
·
James M. Cleary
, Martin Henner Voss
, et al.
·
Journal of Clinical Oncology
·
12
Debio 1347, an oral FGFR inhibitor: Results from a first-in-human, phase I dose-escalation study in patients with FGFR genomically activated advanced solid tumors.
2017
·
Martin Henner Voss
, Cinta Hierro
, et al.
·
Journal of Clinical Oncology
·
12
First-in-human clinical trial design of a first-in-class theranostic approach with a peptide-based radioligand targeting CA IX-expressing tumors.
2023
·
Darren R. Feldman
, Ben Tran
, et al.
·
Journal of Clinical Oncology
·
4
Sequence, exon–intron organization, transcription and mutational analysis of prnA, the gene encoding the transcriptional activator of the prn gene cluster in Aspergillus nidulans
1999
·
Béatrice Cazelle
, Anna Pokorska
, et al.
·
Molecular Microbiology
·
2
First-in-human safety, imaging and dosimetry of [68Ga]Ga-DPI-4452, a novel CA IX-targeting peptide, in patients with clear cell renal cell carcinoma.
2024
·
Michael S Hofman
, Ben Tran
, et al.
·
Journal of Clinical Oncology
·
1
PDF
Abstract 2088: The activity of the FGFR selective inhibitor Debio 1347 is correlated with high mRNA expression
2017
·
Franck Brichory
, Anna Pokorska-Bocci
, et al.
·
Cancer Research
·
1
Abstract 4784: FGFR-selective inhibitor Debio 1347 induces tumor regressions in FGFR2-altered gastric cancer PDX models
2016
·
Brichory Franck
, Anna Pokorska-Bocci
, et al.
·
Cancer Research
·
1
Abstract 5738: Beyond bulk: Resolving RNASeq/mass spectrometry/IHC discrepancies with multiplexed spatial profiling and 3D cluster analysis to refine HER3 (bs)Ab and (bs)ADC therapeutic strategies
2026
·
Jeannette Fuchs
, Christophe Mas
, et al.
·
Cancer Research
D1.3 Ethics Plan
2025
·
Vlassis, Antonios
, Salvatori, Lidia
, et al.
·
Zenodo (CERN European Organization for Nuclear Research)
Supplementary Table S2 from Evaluating Debio 1347 in Patients with FGFR Fusion-Positive Advanced Solid Tumors from the FUZE Multicenter, Open-Label, Phase II Basket Trial
2024
·
Petros Grivas
, Elena Garralda
, et al.
Supplementary Table S5 from Evaluating Debio 1347 in Patients with FGFR Fusion-Positive Advanced Solid Tumors from the FUZE Multicenter, Open-Label, Phase II Basket Trial
2024
·
Petros Grivas
, Elena Garralda
, et al.
Supplementary Figure S2 from Evaluating Debio 1347 in Patients with FGFR Fusion-Positive Advanced Solid Tumors from the FUZE Multicenter, Open-Label, Phase II Basket Trial
2024
·
Petros Grivas
, Elena Garralda
, et al.
Supplementary Methods S1 from Evaluating Debio 1347 in Patients with FGFR Fusion-Positive Advanced Solid Tumors from the FUZE Multicenter, Open-Label, Phase II Basket Trial
2024
·
Petros Grivas
, Elena Garralda
, et al.
Show more works
View as search
Works count:
50
Citation count:
673
H-index:
12
I10-index:
14
Year
Topic
Type
